Latest news
Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline - TipRanksTipRanks · Thu, 30 Jul 2026 12:54:25 GMTMesoblast (ASX:MSB) Is Back in Focus After RYONCIL Revenue Reaches US$115 Million - KalkineKalkine · Thu, 30 Jul 2026 07:00:00 GMTMesoblast posts $36M Ryoncil revenue in Q4, holds $103M cash - scanx.tradescanx.trade · Thu, 30 Jul 2026 07:00:00 GMTMesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch - The Manila TimesThe Manila Times · Thu, 30 Jul 2026 01:15:08 GMTMesoblast reports $115M Ryoncil revenue in firs... - PluangPluang · Thu, 30 Jul 2026 01:11:43 GMTMesoblast reports $115M revenue in first year p... - PluangPluang · Thu, 30 Jul 2026 01:11:42 GMTMesoblast Slips Even as Ryoncil Delivers Its First Full Year of Revenue - KalkineKalkine · Tue, 28 Jul 2026 12:42:00 GMTWhy Is Mesoblast Lifts on Ryoncil Sales Milestone (ASX:MSB)? - Kalkine MediaKalkine Media · Tue, 28 Jul 2026 07:00:00 GMT